Download video

Dr. Chau on CheckMate577 Study in Esophageal/GEJ Cancer

79 views

OncLive

7 years ago

Dr. Chau on CheckMate577 Study in Esophageal/GEJ Cancer

Dr. Chau on CheckMate577 Study in Esophageal/GEJ Cancer

Dr. Chau on CheckMate577 Study in Esophageal\/GEJ Cancer
1:43
Dr. Chau on CheckMate577 Study in Esophageal\/GEJ Cancer
by OncLive
Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal\/GEJ Cancer
1:19
Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal\/GEJ Cancer
by OncLive
Advances in adjuvant and 1L immune checkpoint blockade for gastric and esophageal cancer
4:29
Advances in adjuvant and 1L immune checkpoint blockade for gastric and esophageal cancer
by VJOncology
Checkmate 577 - Is Nivolumab adjuvant the standard of care in esophagus and GEJ?
13:47
Checkmate 577 - Is Nivolumab adjuvant the standard of care in esophagus and GEJ?
by Vinay Prasad MD MPH
Geoffrey Y. Ku, MD, provides perspective on the CheckMate-577 clinical study presented at ESMO 2020
3:42
Geoffrey Y. Ku, MD, provides perspective on the CheckMate-577 clinical study presented at ESMO 2020
by OBRoncology
Checkmate577: nivolumab in EC\/GEJC
5:18
Checkmate577: nivolumab in EC\/GEJC
by VJOncology
Nivolumab for oesophageal cancer following chemoradiation therapy
8:16
Nivolumab for oesophageal cancer following chemoradiation therapy
by ecancer
Nivolumab for perioperative esophageal and gastroesophageal cancer: CheckMate 577
3:12
Nivolumab for perioperative esophageal and gastroesophageal cancer: CheckMate 577
by VJOncology
Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting
11:12
Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting
by European Society for Medical Oncology (ESMO)
Immunotherapy Management of Early and Advanced Gastric, Esophageal, GEJ, and Colorectal Cancers
1:04:22
Immunotherapy Management of Early and Advanced Gastric, Esophageal, GEJ, and Colorectal Cancers
by PeerView Oncology
Dr. Ahn on Neoadjuvant Treatments for Patients With Gastric Cancer
1:49
Dr. Ahn on Neoadjuvant Treatments for Patients With Gastric Cancer
by OncLive
Treating Unresectable or Metastatic Gastric\/GEJ Cancers
5:06
Treating Unresectable or Metastatic Gastric\/GEJ Cancers
by OncLive
New Data on Adjuvant Treatment of Esophageal Cancer
10:45
New Data on Adjuvant Treatment of Esophageal Cancer
by PracticeUpdate
Nivolumab With or Without Ipilimumab in Gastroesophageal Junction Cancer
3:47
Nivolumab With or Without Ipilimumab in Gastroesophageal Junction Cancer
by Targeted Oncology
CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC\/GEJC\/EAC
1:44
CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC\/GEJC\/EAC
by VJOncology
Can nivolimumab aid in preventing gastrointestinal cancer progression?
1:56
Can nivolimumab aid in preventing gastrointestinal cancer progression?
by VJOncology
CheckMate 649: 1L nivo + chemotherapy improves OS
6:54
CheckMate 649: 1L nivo + chemotherapy improves OS
by VJOncology
Emerging Nivolumab Strategies in Gastric\/GEJ Cancers
4:49
Emerging Nivolumab Strategies in Gastric\/GEJ Cancers
by OncLive
Challenges associated with implementing ctDNA for MRD monitoring in breast cancer
1:04
Challenges associated with implementing ctDNA for MRD monitoring in breast cancer
by VJOncology
Long-term results from CheckMate 040: nivolumab + ipilimumab in advanced HCC
4:58
Long-term results from CheckMate 040: nivolumab + ipilimumab in advanced HCC
by VJOncology